Compare ACDC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | CMPS |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 598.7M |
| IPO Year | 2022 | 2020 |
| Metric | ACDC | CMPS |
|---|---|---|
| Price | $4.49 | $6.36 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $6.13 | ★ $16.43 |
| AVG Volume (30 Days) | ★ 1.5M | 1.5M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,960,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $2.25 |
| 52 Week High | $10.70 | $7.09 |
| Indicator | ACDC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 62.92 |
| Support Level | $4.04 | $4.90 |
| Resistance Level | $4.41 | $5.57 |
| Average True Range (ATR) | 0.30 | 0.35 |
| MACD | 0.11 | 0.14 |
| Stochastic Oscillator | 98.59 | 86.10 |
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.